HTORR Ocular Tissue Resource for Alzheimer's Disease Research
HTORR Ocular Tissue Resource for Alzheimer's Disease Research
批准号:
10284285
负责人:
Thomas J Bell
金额:
$33.44万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-01-09 至 2023-06-30
关键词:
AddressAdministrative SupplementAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAmericanAwardAwarenessBiomedical ResearchBrain imagingCaregiversClinicClinical TrialsCollectionCommunitiesDataDementiaDevelopmentDiagnosticDiseaseDisease ProgressionEarly DiagnosisEnsureFunctional disorderFundingGrantHealthcare SystemsHumanImpaired cognitionImpairmentIndustryInterventionInvestigationMethodologyMethodsNeurodegenerative DisordersNeurologicOphthalmologyOrganParentsPathogenesisPathologicPatientsPlayPrincipal InvestigatorProceduresProcessPublicationsReproducibilityResearchResearch PersonnelResearch PriorityResourcesRetinal DegenerationScientific Advances and AccomplishmentsServicesShippingStandardizationTherapeuticTissuesTranslatingUnited States National Institutes of HealthWorkbaseblood-based biomarkercohortdetection methodearly detection biomarkersexperiencehuman old age (65+)human tissueimprovedinterestocular imagingpre-clinicalpreservationprogramsrecruittargeted biomarkertissue resourcetranslational studytreatment strategy
中文摘要
项目主任/首席研究员(Bell, Thomas, J.):
英文摘要
Program Director/Principal Investigator (Bell, Thomas, J.):
Project Summary:
The development of effective diagnostics, treatments or cures for a wide range of diseases requires translational
studies that are directly relevant to human pathophysiology. The use of human biospecimens plays a key role
in accelerating scientific discoveries across the entire spectrum of biomedical research, including
neurodegenerative diseases such as Alzheimer's disease and related dementias (AD/ADRD). Evidence from
clinical trials suggests that preclinical interventions may be key to slowing AD/ADRD disease progression
(Dehghani et al, 2018). However, this treatment strategy requires early detection, which highlights the need for
improved diagnostics for AD/ADRD. While much progress has been made with brain imaging and blood-based
biomarkers, the detection methods remain invasive and expensive. Ocular-based pathological changes
represent a potential target for biomarker investigation. To further investigate the ocular pathogenesis in
AD/ADRD, investigators require access to a unique human tissue resource that could provide rigorous,
reproducible, and uniform collection of human ocular and neurological tissue from defined cohorts of healthy and
AD/ADRD donors. Access to such a resource would be critical to ensuring consistent, predictive, and
reproducible experimental results that could be translated to the clinic for AD/ADRD patients. The National
Disease Research Interchange (NDRI) is a 501(c)(3), not-for-profit organization that remains at the forefront of
coordinating biospecimen procurement to match the needs of advancing scientific experimental methodologies,
and enabling cutting-edge research. For over 30 years, NDRI has received NIH funding for the parent award to
this administrative supplement, the Human Tissue and Organs for Research Resource (HTORR) Grant Number:
U42OD011158. NDRI is applying for the NOT-AG-20-034, Notice of Special Interest (NOSI) to expand its focus
beyond the scope of HTORR to develop and implement the Ocular Tissue Resource for AD/ADRD Research
(OTR-AD). For the current proposal to develop and implement the OTR-AD, NDRI will: 1) work with investigators
and key stakeholders at NEI to identify high-priority ocular biospecimen needs to support AD/ADRD research,
2) screen, authorize, recover, and process ocular and other neurological biospecimens from eligible post mortem
donors, and 3) distribute biospecimens to approved investigators and promote awareness of OTR-AD to recruit
new investigators.
In doing so, the biospecimen collection and preservation methods will be optimized to the experimental
hypotheses and procedures for each ADBR study using NDRI's experience in coordinating standardized
procurement, processing, preservation and shipping methods and maintaining industry best practices and
standards regarding the donation of human tissue for research. The overall objective of the OTR-AD is to provide
well-annotated ocular and neurological tissue from defined cohorts of healthy and AD/ADRD donors that are
suitable to generate high-quality, reproducible data for scientific review and publication to meet the needs of
investigators and support the advancement of AD/ADRD research.
Relevance: As the most common cause of dementia, AD is a devastating, progressive neurodegenerative
disease that affects an estimated 5.8 million Americans age 65 and over (Alzheimer's Association et al, 2020)
and has a significant burden on the US healthcare system as well as caregivers. As of yet, there are no disease-
modifying treatment options available for AD/ADRD patients, making this a high priority for the research
community. Disappointing clinical trial results evaluating potential disease-modifying treatments in patients with
AD/ADRD have shifted the therapeutic focus to preclinical intervention (Crous-Bou et al, 2017), which requires
improved diagnostics. While significant advances continue to be made with the identification of blood-based
biomarkers for AD/ADRD, a parallel approach could be the use of ocular imaging or other ocular biomarkers for
early detection. The objective of this proposal is to provide ocular biospecimens from post mortem AD/ADRD
donors, as well as non-diseased control donors for the Ocular Tissue Resource for AD/ADRD Research (OTR-
AD) that are suitable to support critical lines of investigation that address key issues related to ocular
pathogenesis in the disease.
OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tissue Procurement Center (TPC) Supporting the Somatic Mosaicism across Human Tissues (SMaHT) Network
-
批准号:10661300
-
项目类别:
-
资助金额:$300.0万
-
财政年份:2023
-
负责人:Thomas J Bell
-
依托单位:
HTORR High Priority Alzheimer's Disease and Related Dementias Human Biospecimen Resource
-
批准号:10489968
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2021
-
负责人:Thomas J Bell
-
依托单位:
Research Resource for Human Organs and Tissues (U42)
-
批准号:9761605
-
项目类别:
-
资助金额:$131.83万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
Research Resource for Human Organs and Tissues (U42)
-
批准号:10628539
-
项目类别:
-
资助金额:$27.03万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
Research Resource for Human Organs and Tissues (U42)
-
批准号:10004191
-
项目类别:
-
资助金额:$131.83万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
Alzheimer's-focused Administrative Supplements for NIH Grants that are not focused on Alzheimer's disease.
-
批准号:10121141
-
项目类别:
-
资助金额:$35.02万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
HTORR A&R COLD STORAGE ADMINSTRATIVE SUPPLEMENT APPLICATION
-
批准号:10600579
-
项目类别:
-
资助金额:$10.19万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
Research Resource for Human Organs and Tissues (U42)
-
批准号:10434059
-
项目类别:
-
资助金额:$131.83万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
HTORR/ NIAID High Priority HIV Human Biospecimen Recovery Program
-
批准号:10405146
-
项目类别:
-
资助金额:$24.26万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
Research Resource for Human Organs and Tissues (U42)
-
批准号:10208991
-
项目类别:
-
资助金额:$131.83万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
Research Resource for Human Organs and Tissues
-
批准号:10555977
-
项目类别:
-
资助金额:$123.81万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
HTORR/ NIMH ASD and Control Brain Recovery Project
-
批准号:10191329
-
项目类别:
-
资助金额:$29.59万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
HTORR/ NIMH ASD and Control Brain Recovery Project
-
批准号:10429174
-
项目类别:
-
资助金额:$29.88万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
Core Management
-
批准号:10555979
-
项目类别:
-
资助金额:$123.81万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
HTORR Rare Disease Diversity Supplement
-
批准号:10608762
-
项目类别:
-
资助金额:$8.69万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
HTORR/ NIAID High Priority HIV Human Biospecimen Recovery Program
-
批准号:10175273
-
项目类别:
-
资助金额:$26.49万
-
财政年份:1989
-
负责人:Thomas J Bell
-
依托单位:
海外基金